Subclinical hypothyroidism and subclinical hyperthyroidism

Expert Review of Endocrinology and Metabolism

Volumn 5, Issue 3, 2010, Pages 359-373

  Fatourechi, Vahab ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antithyroid antibody; Cardiac risk factor; Hyperthyroidism; Hypothyroidism; Subclinical hyperthyroidism; Subclinical hypothyroidism; Thyroid stimulating hormone screening; Thyrotropin; Thyroxine therapy

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; DOMPERIDONE; DOPAMINE; HETEROPHILE ANTIBODY; LIOTHYRONINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOCLOPRAMIDE; PLACEBO; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE;

ADDISON DISEASE; CARDIOVASCULAR DISEASE; CIRCADIAN RHYTHM; CONGESTIVE HEART FAILURE; DEMENTIA; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; EUTHYROID SICK SYNDROME; FIRST TRIMESTER PREGNANCY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HORMONE SUBSTITUTION; HUMAN; HYPEREMESIS GRAVIDARUM; HYPERTHYROIDISM; HYPOTHYROIDISM; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MORTALITY; MUSCLE WEAKNESS; NORMAL VALUE; OSTEOPENIA; POSTPARTUM THYROIDITIS; PRIORITY JOURNAL; REVIEW; SCREENING; SIDE EFFECT; SUBACUTE THYROIDITIS; SUPRAVENTRICULAR PREMATURE BEAT; THYROID CARCINOMA; THYROID DISEASE; THYROTROPIN BLOOD LEVEL; THYROTROPIN SECRETING ADENOMA;

EID: 77952512301     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/eem.10.2     Document Type: Review

References (142)

1. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr. Rev. 29 (1), 76-131 (2008). Important and thorough review article by two researchers with an interest in the subject.
2. Cooper DS. Approach to the patient with subclinical hyperthyroidism. J. Clin. Endocrinol. Metab. 92 (1), 3-9 (2007).
3. 3 in normal subjects: a clue to the understanding of subclinical thyroid disease. J. Clin. Endocrinol. Metab. 87 (3), 1068-1072 (2002).
4. Ross DS. Serum thyroid-stimulating hormone measurement for assessment of thyroid function and disease. Endocrinol. Metab. Clin. North Am. 30 (2), 245-264, vii (2001).
5. McDermott MT, Ridgway EC. Subclinical hypothyroidism is mild thyroid failure and should be treated. J. Clin. Endocrinol. Metab. 86 (10), 4585-4590 (2001).
6. Spencer CA. Clinical utility and costeffectiveness of sensitive thyrotropin assays in ambulatory and hospitalized patients. Mayo Clin. Proc. 63 (12), 1214-1222 (1988).
7. 4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocrinol. Metab. 87 (2), 489-499 (2002). Landmark paper defining the frequency of subclinical thyroid dysfunction in the USA by studying a large cross-section of the US population.
8. Surks MI, Ortiz E, Daniels GH et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291 (2), 228-238 (2004). Commissioned by several endocrine societies, includes an expert review of the literature and evidence-based recommendations. It concluded that, on the basis of the evidence, there was no adverse effect or benefit of therapy of serum thyroid-stimulating hormone (TSH) less than 10.0 mIU/l. The paper became controversial and has been rebutted by the same societies that commissioned it.
9. Wartofsky L, Dickey RA. The evidence for a narrower thyrotropin reference range is compelling. J. Clin. Endocrinol. Metab. 90 (9), 5483-5488 (2005).
10. Surks MI, Hollowell JG. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. J. Clin. Endocrinol. Metab. 92 (12), 4575-4582 (2007). Raised the possibility, for the first time, that higher frequency of mildly elevated TSH in older individuals may not be due to autoimmune disease but may indicate a higher upper limit normal for the older population, and normal serum TSH may be age dependent.
11. Surks MI, Goswami G, Daniels GH. The thyrotropin reference range should remain unchanged. J. Clin. Endocrinol. Metab. 90 (9), 5489-5496 (2005).
12. Fatourechi V, Klee GG, Grebe SK et al. Effects of reducing the upper limit of normal TSH values. JAMA 290 (24), 3195-3196 (2003).
13. Spencer CA, Hollowell JG, Kazarosyan M, Braverman LE. National Health and Nutrition Examination Survey III thyroid-stimulating hormone (TSH) - thyroperoxidase antibody relationships demonstrate that TSH upper reference limits may be skewed by occult thyroid dysfunction. J. Clin. Endocrinol. Metab. 92 (11), 4236-4240 (2007).
14. Gharib H, Tuttle RM, Baskin HJ, Fish LH, Singer PA, McDermott MT. Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. J. Clin. Endocrinol. Metab. 90 (1), 581-585 (2005).
15. Gharib H, Tuttle RM, Baskin HJ, Fish LH, Singer PA, McDermott MT; American Association of Clinical Endocrinologists; American Thyroid Association; Endocrine Society. Consensus Statement #1: subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. Thyroid 15 (1), 24-28 (2005).
16. Vanderpump MP, Tunbridge WM, French JM et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin. Endocrinol. (Oxf.) 43 (1), 55-68 (1995).
17. Brabant G, Prank K, Ranft U et al. Physiological regulation of circadian and pulsatile thyrotropin secretion in normal man and woman. J. Clin. Endocrinol. Metab. 70 (2), 403-409 (1990).
18. Park YJ, Lee EJ, Lee YJ et al. Subclinical hypothyroidism (SCH) is not associated with metabolic derangement, cognitive impairment, depression or poor quality of life (QoL) in elderly subjects. Arch. Gerontol. Geriatr. 50 (3), e68-e73 (2010).
19. Glinoer D. What happens to the normal thyroid during pregnancy? Thyroid 9 (7), 631-635 (1999).
20. Brabant G, Beck-Peccoz P, Jarzab B et al. Is there a need to redefine the upper normal limit of TSH? Eur. J. Endocrinol. 154 (5), 633-637 (2006).
21. 4 are significantly influenced by race and age in an urban outpatient medical practice. Clin. Endocrinol (Oxf.) 70 (5), 788-793 (2009).
22. Ladenson PW, Singer PA, Ain KB et al. American Thyroid Association guidelines for detection of thyroid dysfunction. Arch. Intern. Med. 60 (11), 1573-1575 (2000) ;
23. Erratum in Arch. Intern. Med. 161 (2), 284 (2001).
24. Helfand M, Redfern CC; American College of Physicians. Clinical guideline, part 2: screening for thyroid disease: an update. Ann. Intern. Med. 129 (2), 144-158 (1998) ;
25. Erratum in Ann. Intern. Med. 130 (3), 246 (1999).
26. Helfand M; U. S. Preventive Services Task Force. Screening for subclinical thyroid dysfunction in nonpregnant adults: a summary of the evidence for the U. S. Preventive Services Task Force. Ann. Intern. Med. 140 (2), 128-141 (2004).
27. Hollowell JG, LaFranchi S, Smallridge RC, Spong CY, Haddow JE, Boyle CA. 2004 where do we go from here? Summary of working group discussions on thyroid function and gestational outcomes. Thyroid 15 (1), 72-76 (2005).
28. Haddow JE, Palomaki GE, Allan WC et al Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N. Engl. J. Med. 341 (8), 549-555 (1999). Influenced management of subclinical hypothyroidism in pregnancy. It has resulted in aggressive case finding and therapy and has strengthened the argument for universal screening with TSH in pregnancy. The authors showed reduced IQ in the offspring of mothers who had elevated TSH.
29. Surks MI. Commentary: subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. J. Clin. Endocrinol. Metab. 90 (1), 586-587 (2005).
30. Vaidya B, Anthony S, Bilous M et al Detection of thyroid dysfunction in early pregnancy: universal screening or targeted high-risk case finding? J. Clin. Endocrinol Metab. 92 (1), 203-207 (2007).
31. Committee on Patient Safety and Quality Improvement; Committee on Professional Liability. ACOG Committee Opinion No. 381: subclinical hypothyroidism in pregnancy. Obstet. Gynecol. 110 (4), 959-960 (2007).
32. Radacsi A, Bernard W, Feldkamp J, Horster FA, Szabolcs I. Follow up of thyroid hormone parameters in chronically ill geriatric patients: screening for thyroid disorders at hospital admission justified. Exp. Clin. Endocrinol. Diabetes 108 (4), 290-293 (2000).
33. Fatourechi V. Subclinical hypothyroidism: an update for primary care physicians. Mayo Clin. Proc. 84 (1), 65-71 (2009).
34. Cooper DS. Subclinical thyroid disease: a clinician's perspective. Ann. Intern. Med. 129 (2), 135-138 (1998).
35. Cooper DS. Clinical practice: subclinical hypothyroidism. N. Engl. J. Med. 345 (4), 260-265 (2001).
36. Franklyn JA. Subclinical thyroid disorders: consequences and implications for treatment. Ann. Endocrinol. (Paris) 68 (4), 229-230 (2007).
37. Peeters RP, van der Deure WM, Visser TJ. Genetic variation in thyroid hormone pathway genes: polymorphisms in the TSH receptor and the iodothyronine deiodinases. Eur. J. Endocrinol. 155 (5), 655-662 (2006).
38. Diez JJ, Iglesias P. An analysis of the natural course of subclinical hyperthyroidism. Am. J. Med. Sci. 337 (4), 225-232 (2009).
39. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch. Intern. Med. 160 (4), 526-534 (2000).
40. Choi AR, Manning P. Overshooting the mark: subclinical hyperthyroidism secondary to excess thyroid hormone treatment may be more prevalent than we realise. NZ Med. J. 122 (1289), 93-94 (2009).
41. Charkes ND. The many causes of subclinical hyperthyroidism. Thyroid 6 (5), 391-396 (1996).
42. Hovens GC, Stokkel MP, Kievit J et al. Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 92 (7), 2610-2615 (2007).
43. Bjorndal MM, Sandmo Wilhelmsen K, Lu T, Jorde R. Prevalence and causes of undiagnosed hyperthyroidism in an adult healthy population: the Tromso study. J. Endocrinol. Invest. 31 (10), 856-860 (2008).
44. Diez JJ. Hyperthyroidism in patients older than 55 years: an analysis of the etiology and management. Gerontology 49 (5), 316-323 (2003).
45. Toft AD. Clinical practice: subclinical hyperthyroidism. N. Engl. J. Med. 345 (7), 512-516 (2001).
46. Casey BM, Dashe JS, Wells CE, McIntire DD, Leveno KJ, Cunningham FG. Subclinical hyperthyroidism and pregnancy outcomes. Obstet. Gynecol. 107 (2 Pt 1), 337-341 (2006).
47. Marx H, Amin P, Lazarus JH. Hyperthyroidism and pregnancy. BMJ 336 (7645), 663-667 (2008) ;
48. Erratum in BMJ DOI: 10.1136/bmj.39545.531771. AD (2010).
49. Lazarus JH. Thyroid disorders associated with pregnancy: etiology, diagnosis, and management. Treat. Endocrinol. 4 (1), 31-41 (2005).
50. Woeber KA. Observations concerning the natural history of subclinical hyperthyroidism. Thyroid 15 (7), 687-691 (2005).
51. Biondi B, Palmieri EA, Klain M, Schlumberger M, Filetti S, Lombardi G. Subclinical hyperthyroidism: clinical features and treatment options. Eur. J. Endocrinol. 152 (1), 1-9 (2005).
52. Eustatia-Rutten CF, Corssmit EP, Pereira AM et al. Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial. Clin. Endocrinol. (Oxf.) 64 (3), 284-291 (2006).
53. Samuels MH. Cognitive function in untreated hypothyroidism and hyperthyroidism. Curr. Opin. Endocrinol Diabetes Obes. 15 (5), 429-433 (2008).
54. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 358 (9285), 861-865 (2001).
55. Ochs N, Auer R, Bauer DC et al. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann. Intern. Med. 148 (11), 832-845 (2008). Analyzed the possibility of subclinical hypothyroidism as a cardiovascular risk factor.
56. Biondi B, Palmieri EA, Fazio S et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J. Clin. Endocrinol. Metab. 85 (12), 4701-4705 (2000).
57. Biondi B, Fazio S, Cuocolo A et al. Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine. J. Clin. Endocrinol. Metab. 81 (12), 4224-4228 (1996).
58. Owecki M, Michalak A, Nikisch E, Sowinski J. Prolonged ventricular repolarization measured by corrected QT interval (QTc) in subclinical hyperthyroidism. Horm. Metab. Res. 38 (1), 44-47 (2006).
59. Rodondi N, Bauer DC, Cappola AR et al. Subclinical thyroid dysfunction, cardiac function, and the risk of heart failure: the Cardiovascular Health Study. J. Am. Coll. Cardiol. 52 (14), 1152-1159 (2008).
60. Rosario PW, Borges MA, Purisch S. Effects of the restoration of euthyroidism after chronic suppressive therapy with levothyroxine in patients with thyroid cancer. Endocrinologist 19 (2), 58-59 (2009)
61. Iqbal A, Schirmer H, Lunde P, Figenschau Y, Rasmussen K, Jorde R. Thyroid stimulating hormone and left ventricular function. J. Clin. Endocrinol. Metab. 92 (9) 3504-3510 (2007).
62. Sawin CT. Subclinical hyperthyroidism and atrial fibrillation. Thyroid 12 (6), 501-503 (2002).
63. Gammage MD, Parle JV, Holder RL et al. Association between serum free thyroxine concentration and atrial fibrillation. Arch. Intern. Med. 167 (9), 928-934 (2007).
64. Ross DS. Hyperthyroidism, thyroid hormone therapy, and bone. Thyroid 4 (3), 319-326 (1994).
65. Kim DJ, Khang YH, Koh JM, Shong YK, Kim GS. Low normal TSH levels are associated with low bone mineral density in healthy postmenopausal women. Clin. Endocrinol. (Oxf.) 64 (1), 86-90 (2006).
66. Bauer DC, Ettinger B, Nevitt MC, Stone KL; Study of Osteoporotic Fractures Research Group. Risk for fracture in women with low serum levels of thyroidstimulating hormone. Ann. Intern. Med. 134 (7), 561-568 (2001).
67. Morris MS. The association between serum thyroid-stimulating hormone in its reference range and bone status in postmenopausal American women. Bone 40 (4), 1128-1134 (2007).
68. Reverter JL, Holgado S, Alonso N, Salinas I, Granada ML, Sanmarti A. Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma. Endocr. Relat. Cancer 12 (4), 973-981 (2005).
69. Kalmijn S, Mehta KM, Pols HA, Hofman A, Drexhage HA, Breteler MM. Subclinical hyperthyroidism and the risk of dementia: the Rotterdam study. Clin. Endocrinol. (Oxf.) 53 (6), 733-737 (2000).
70. Dobert N, Hamscho N, Menzel C et al. Subclinical hyperthyroidism in dementia and correlation of the metabolic index in FDG-PET. Acta Med. Austriaca 30 (5), 130-133 (2003).
71. van Osch LA, Hogervorst E, Combrinck M, Smith AD. Low thyroid-stimulating hormone as an independent risk factor for Alzheimer disease. Neurology 62 (11), 1967-1971 (2004).
72. Roberts LM, Pattison H, Roalfe A et al. Is subclinical thyroid dysfunction in the elderly associated with depression or cognitive dysfunction? Ann. Intern. Med. 145 (8), 573-581 (2006).
73. Brennan MD, Powell C, Kaufman KR, Sun PC, Bahn RS, Nair KS. The impact of overt and subclinical hyperthyroidism on skeletal muscle. Thyroid 16 (4), 375-380 (2006).
74. Greenlund LJ, Nair KS, Brennan MD. Changes in body composition in women following treatment of overt and subclinical hyperthyroidism. Endocr. Pract. 14 (8), 973-978 (2008).
75. Bober SA, McGill AC, Tunbridge WM. Thyroid function in hyperemesis gravidarum. Acta Endocrinol. (Copenh.) 111 (3), 404-410 (1986).
76. Dorr M, Ruppert J, Robinson DM, Kors JA, Felix SB, Volzke H. The relation of thyroid function and ventricular repolarization: decreased serum thyrotropin levels are associated with short rate-adjusted QT intervals. J. Clin. Endocrinol. Metab. 91 (12), 4938-4942 (2006).
77. Gow SM, Nicol K, Seth J, Caldwell G, Toft AD, Beckett GJ. Laboratory and diagnostic performance of a coated well immunoradiometric assay for serum thyrotrophin. Ann. Clin. Biochem. 24 (Pt 3), 273-278 (1987).
78. Eustatia-Rutten CF, Corssmit EP, Heemstra KA et al. Autonomic nervous system function in chronic exogenous subclinical thyrotoxicosis and the effect of restoring euthyroidism. J. Clin. Endocrinol. Metab. 93 (7), 2835-2841 (2008).
79. Goichot B, Sapin R, Schlienger JL. Subclinical hyperthyroidism: considerations in defining the lower limit of the thyrotropin reference interval. Clin. Chem. 55 (3), 420-424 (2009).
80. Haden ST, Marqusee E, Utiger RD. Subclinical hyperthyroidism. Endocrinologist 6 (4), 322-327 (1996).
81. Burch HB, Shakir F, Fitzsimmons TR, Jaques DP, Shriver CD. Diagnosis and management of the autonomously functioning thyroid nodule: the Walter Reed Army Medical Center experience, 1975-1996. Thyroid 8 (10), 871-880 (1998).
82. Col NF, Surks MI, Daniels GH. Subclinical thyroid disease: clinical applications. JAMA 291 (2), 239-243 (2004).
83. Laurberg P, Andersen S, Bulow Pedersen I, Carle A. Hypothyroidism in the elderly: pathophysiology, diagnosis and treatment. Drugs Aging 22 (1), 23-38 (2005).
84. Tunbridge WM, Vanderpump MP. Population screening for autoimmune thyroid disease. Endocrinol. Metab. Clin. North Am. 29 (2), 239-253, v (2000).
85. Fatourechi V, Lankarani M, Schryver PG, Vanness DJ, Long KH, Klee GG. Factors influencing clinical decisions to initiate thyroxine therapy for patients with mildly increased serum thyrotropin (5.1-10.0 mIU/L). Mayo Clin. Proc. 78 (5), 554-560 (2003).
86. Chu JW, Crapo LM. The treatment of subclinical hypothyroidism is seldom necessary. J. Clin. Endocrinol. Metab. 86 (10), 4591-4599 (2001).
87. Rosario PW, Bessa B, Valadao MM, Purisch S. Natural history of mild subclinical hypothyroidism: prognostic value of ultrasound. Thyroid 19 (1), 9-12 (2009).
88. Diez JJ, Iglesias P. Spontaneous subclinical hypothyroidism in patients older than 55 years: an analysis of natural course and risk factors for the development of overt thyroid failure. J. Clin. Endocrinol. Metab. 89 (10), 4890-4897 (2004).
89. Kong WM, Sheikh MH, Lumb PJ et al A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism. Am. J. Med. 112 (5), 348-354 (2002) ;
90. Erratum in Am. J. Med. 113 (3), 264 (2002). One of the first randomized studies that concentrated on patients with serum TSH levels under 10.0 mIU/l. These patients showed no benefit of thyroxine therapy.
91. Cooper DS, Halpern R, Wood LC, Levin AA, Ridgway EC. l-thyroxine therapy in subclinical hypothyroidism: a doubleblind, placebo-controlled trial. Ann. Intern. Med. 101 (1), 18-24 (1984).
92. Gussekloo J, van Exel E, de Craen AJ, Meinders AE, Frolich M, Westendorp RG. Thyroid status, disability and cognitive function, and survival in old age. JAMA 292 (21), 2591-2599 (2004).
93. Jorde R, Waterloo K, Storhaug H, Nyrnes A, Sundsfjord J, Jenssen TG. Neuropsychological function and symptoms in subjects with subclinical hypothyroidism and the effect of thyroxine treatment. J. Clin. Endocrinol. Metab. 91 (1), 145-153 (2006).
94. Zhu DF, Wang ZX, Zhang DR et al. fMRI revealed neural substrate for reversible working memory dysfunction in subclinical hypothyroidism. Brain 129 (Pt 11), 2923-2930 (2006).
95. Wu T, Flowers JW, Tudiver F, Wilson JL, Punyasavatsut N. Subclinical thyroid disorders and cognitive performance among adolescents in the United States. BMC Pediatr. 6, 12 (2006).
96. Villar HC, Saconato H, Valente O, Atallah AN. Thyroid hormone replacement for subclinical hypothyroidism. Cochrane Database Syst. Rev. (3), CD003419 (2007).
97. Danese MD, Ladenson PW, Meinert CL, Powe NR. Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J. Clin. Endocrinol. Metab. 85 (9), 2993-3001 (2000).
98. Erem C. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity. Clin. Endocrinol. (Oxf.) 64 (3), 323-329 (2006).
99. Al Sayed A, Al Ali N, Bo Abbas Y, Alfadhli E. Subclinical hypothyroidism is associated with early insulin resistance in Kuwaiti women. Endocr. J. 53 (5), 653-657 (2006).
100. Takashima N, Niwa Y, Mannami T, Tomoike H, Iwai N. Characterization of subclinical thyroid dysfunction from cardiovascular and metabolic viewpoints: the Suita study. Circ. J. 71 (2), 191-195 (2007).
101. Hueston WJ, King DE, Geesey ME. Serum biomarkers for cardiovascular inflammation in subclinical hypothyroidism. Clin. Endocrinol. (Oxf.) 63 (5), 582-587 (2005).
102. Meek S, Smallridge RC. Effect of thyroid hormone replacement on methioninestimulated homocysteine levels in patients with subclinical hypothyroidism: a randomized, double-blind, placebocontrolled study Endocr. Pract. 12 (5), 529-534 (2006).
103. Duntas LH, Wartofsky L. Cardiovascular risk and subclinical hypothyroidism: focus on lipids and new emerging risk factors: what is the evidence? Thyroid 17 (11), 1075-1084 (2007).
104. Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver JU. The beneficial effect of l-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. J. Clin. Endocrinol. Metab. 92 (5), 1715-1723 (2007).
105. Perez A, Cubero JM, Sucunza N et al. Emerging cardiovascular risk factors in subclinical hypothyroidism: lack of change after restoration of euthyroidism. Metabolism 53 (11), 1512-1515 (2004).
106. Erdal M, Sahin M, Saglam K et al. Increased serum chitotriosidase activity following restoration of euthyroidism in patients with subclinical hypothyroidism. Intern. Med. 47 (14), 1309-1314 (2008).
107. Bell RJ, Rivera-Woll L, Davison SL, Topliss DJ, Donath S, Davis SR. Well-being, health-related quality of life and cardiovascular disease risk profile in women with subclinical thyroid disease: a community-based study. Clin. Endocrinol (Oxf.) 66 (4), 548-556 (2007).
108. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam study. Ann. Intern. Med. 132 (4), 270-278 (2000). Among the first papers to suggest increased risk for atherosclerosis and myocardial infarction in women with mildly elevated serum TSH.
109. Vanderpump MP, Tunbridge WM, French JM et al. The development of ischemic heart disease in relation to autoimmune thyroid disease in a 20-year follow-up study of an English community. Thyroid 6 (3), 155-160 (1996).
110. Cappola AR, Fried LP, Arnold AM et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 295 (9), 1033-1041 (2006).
111. Rodondi N, Aujesky D, Vittinghoff E, Cornuz J, Bauer DC. Subclinical hypothyroidism and the risk of coronary heart disease: a meta-analysis. Am. J. Med. 119 (7), 541-551 (2006).
112. Singh S, Duggal J, Molnar J, Maldonado F, Barsano CP, Arora R. Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis. Int. J. Cardiol. 125 (1), 41-48 (2008).
113. Haentjens P, Van Meerhaeghe A, Poppe K, Velkeniers B. Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies. Eur. J. Endocrinol. 159 (3), 329-341 (2008).
114. Razvi S, Shakoor A, Vanderpump M, Weaver JU, Pearce SH. The influence of age on the relationship between subclinical hypothyroidism and ischemic heart disease: a metaanalysis. J. Clin. Endocrinol. Metab. 93 (8), 2998-3007 (2008).
115. Atzmon G, Barzilai N, Hollowell JG, Surks MI, Gabriely I. Extreme longevity is associated with increased serum thyrotropin. J. Clin. Endocrinol. Metab. 94 (4), 1251-1254 (2009).
116. Biondi B. Cardiovascular effects of mild hypothyroidism. Thyroid 17 (7), 625-630 (2007).
117. Baycan S, Erdogan D, Caliskan M et al. Coronary flow reserve is impaired in subclinical hypothyroidism. Clin. Cardiol. 30 (11), 562-566 (2007).
118. Owen PJ, Rajiv C, Vinereanu D, Mathew T, Fraser AG, Lazarus JH. Subclinical hypothyroidism, arterial stiffness, and myocardial reserve. J. Clin. Endocrinol. Metab. 91 (6), 2126-2132 (2006).
119. Franzoni F, Galetta F, Fallahi P et al. Effect of l-thyroxine treatment on left ventricular function in subclinical hypothyroidism. Biomed. Pharmacother. 60 (8), 431-436 (2006).
120. Glinoer D. Potential repercussions for the progeny of maternal hypothyroxinemia during pregnancy. Thyroid 10 (1), 59-62 (2000).
121. LaFranchi SH, Haddow JE, Hollowell JG. Is thyroid inadequacy during gestation a risk factor for adverse pregnancy and developmental outcomes? Thyroid 15 (1), 60-71 (2005).
122. Haddow JE; Thyroid Study Group. Subclinical hypothyroidism and pregnancy outcomes. Obstet. Gynecol. 106 (1), 198;
123. author reply 198-199 (2005).
124. Casey BM, Dashe JS, Wells CE et al. Subclinical hypothyroidism and pregnancy outcomes. Obstet. Gynecol. 105 (2), 239-245 (2005).
125. Benhadi N, Wiersinga WM, Reitsma JB, Vrijkotte TG, Bonsel GJ. Higher maternal TSH levels in pregnancy are associated with increased risk for miscarriage, fetal or neonatal death. Eur. J. Endocrinol. 160 (6), 985-991 (2009).
126. Negro R, Formoso G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H. Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on obstetrical complications. J. Clin. Endocrinol. Metab. 91 (7), 2587-2591 (2006).
127. Christ-Crain M, Meier C, Huber PR, Staub JJ, Muller B. Effect of l-thyroxine replacement therapy on surrogate markers of skeletal and cardiac function in subclinical hypothyroidism. Endocrinologist 14 (3), 161-166 (2004).
128. 4 replacement therapy. Clin. Endocrinol. (Oxf.) 51 (2), 237-242 (1999).
129. Caraccio N, Natali A, Sironi A, Baldi S, Frascerra S, Dardano A et al. Muscle metabolism and exercise tolerance in subclinical hypothyroidism: a controlled trial of levothyroxine. J. Clin. Endocrinol. Metab. 90 (7), 4057-4062 (2005).
130. Misiunas A, Niepomniszcze H, Ravera B, Faraj G, Faure E. Peripheral neuropathy in subclinical hypothyroidism. Thyroid 5 (4), 283-286 (1995).
131. Arikan E, Pekindil G, Guldiken S, Pekindil Y. The evaluation of the median nerve in subclinical hypothyroidism by high-resolution sonography. Endocrinologist 15 (4), 209-212 (2005).
132. Haggerty JJ Jr, Garbutt JC, Evans DL et al. Subclinical hypothyroidism: a review of neuropsychiatric aspects. Int. J. Psychiatry Med. 20 (2), 193-208 (1990).
133. Holtmann M, Duketis E, Goth K, Poustka L, Boelte S. Severe affective and behavioral dysregulation in youth is associated with increased serum TSH. J. Affect. Disord. 121 (1-2), 184-188 (2009).
134. Post RM, Kramlinger KG, Joffe RT et al. Rapid cycling bipolar affective disorder: lack of relation to hypothyroidism. Psychiatry Res. 72 (1), 1-7 (1997).
135. Williams MD, Harris R, Dayan CM, Evans J, Gallacher J, Ben-Shlomo Y. Thyroid function and the natural history of depression: findings from the Caerphilly Prospective Study (CaPS) and a metaanalysis. Clin. Endocrinol. (Oxf) 70 (3), 484-492 (2009).
136. Pollock MA, Sturrock A, Marshall K et al. Thyroxine treatment in patients with symptoms of hypothyroidism but thyroid function tests within the reference range: randomised double blind placebo controlled crossover trial. BMJ 323 (7318), 891-895 (2001). Showed that lowering serum TSH from the upper limit to the lower limit of normal did not improve symptoms. Thus, it speaks against lowering the upper limit of normal TSH from 5.0 to 3.0 mIU/l.
137. Santini F, Pinchera A, Marsili A et al. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J. Clin. Endocrinol. Metab. 90 (1), 124-127 (2005).
138. Meier C, Staub JJ, Roth CB et al. TSH-controlled l-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). J. Clin. Endocrinol. Metab. 86 (10), 4860-4866 (2001).
139. Haggerty JJ Jr, Prange AJ Jr. Borderline hypothyroidism and depression. Annu. Rev. Med. 46, 37-46 (1995).
140. Jaeschke R, Guyatt G, Gerstein H et al. Does treatment with l-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism? J. Gen. Intern. Med. 11 (12), 744-749 (1996).
141. Nystrom E, Caidahl K, Fager G, Wikkelso C, Lundberg PA, Lindstedt G. A doubleblind cross-over 12-month study of l-thyroxine treatment of women with 'subclinical' hypothyroidism. Clin. Endocrinol. (Oxf.) 29 (1), 63-75 (1988).
142. Biondi B, Palmieri EA, Lombardi G, Fazio S. Effects of subclinical thyroid dysfunction on the heart. Ann. Intern. Med. 137 (11), 904-914 (2002).